Inspired by genetics.
Driven by patients.
Pioneering medicines for brain disorders.

Praxis Precision Medicines is committed to advancing therapies for genetically defined neurological disorders, with a focus on both rare epilepsies, psychiatric and movement disorders. These three disease areas share a strong scientific link as well as a profound need for new therapeutic options that target the underlying drivers of the diseases.

Founded in 2017, Praxis is pioneering a scientific approach and model that has allowed us to develop medicines with the potential to more precisely treat debilitating neurological conditions.

Why Praxis Precision Medicines?

The word Praxis is from Greek and means the art of taking a complex idea and reducing it to practice. Praxis Precision Medicines is taking new insights from the emerging genetics of complex neuropsychiatric disorders and applying them to develop pioneering new therapies for the patients and families that need them most.

The Praxis Precision Medicines Team

Our leadership team shares a singular vision – to develop transformative medicines for children and adults with neurological diseases. Together, we are advancing a targeted approach to treating these conditions, with the potential to greatly improve the lives of patients. Learn more about our team and what connects us.

Management Team

KIRAN REDDY Chief Executive Officer
Kiran Reddy

Chief Executive Officer

KIRAN REDDY

Chief Executive Officer

Kiran founded Praxis in 2016 as a Venture Partner at Clarus. Prior to Clarus, Kiran was part of the Corporate Strategy leadership team at Biogen where he focused on sourcing new technologies and product opportunities to support the company’s long-term growth. He previously was an Associate Partner at Third Rock Ventures where he supported various portfolio companies while focusing on new company formation, including Foundation Medicine and Sage Therapeutics, where he served at Chief Business Officer. Prior to Third Rock, Kiran was a management consultant at the Lewin Group where he advised biopharma clients on clinical development and commercial strategy. Kiran holds BS, MD and MBA degrees from Georgetown University. He completed his internship in medicine and neurology residency at Harvard / Massachusetts General Hospital, was previously a Howard Hughes fellow, and is a board-certified neurologist.

BERNARD RAVINA Chief Medical Officer
Bernard Ravina

Chief Medical Officer

BERNARD RAVINA

Chief Medical Officer

Bernard joined Praxis from Voyager Therapeutics where he was the company’s Chief Medical Officer with responsibility for all clinical development activities for the company’s neurology portfolio. Prior to Voyager, Bernard spent four years at Biogen as a Medical Director, advancing several of the company’s clinical programs addressing Parkinson’s Disease, stroke, and neuropathic pain. Bernard began his career as an investigator at the National Institute of Neurological Disorders before taking an academic position as the Director of Movement and Neurological Disorders at the University of Rochester Medical Center where he was responsible for executing numerous industry-sponsored clinical trials. Bernard holds a BA in Psychology from Columbia University, and an MS in Clinical Epidemiology from the University of Pennsylvania, and an MD from the Johns Hopkins University School of Medicine.

STEVEN PETROU Chief Scientific Officer
Steven Petrou

Chief Scientific Officer

STEVEN PETROU

Chief Scientific Officer

Steve was one of the founding scientists of Praxis and is the Director of the Florey Institute of Neuroscience and Mental Health. Steve’s research is focused on the functional genetics and genomics of epilepsy, and he has developed several of the first animal models of genetically-defined epilepsies. Using a systems approach, Steve has described how receptor and ion-channel mutations lead to the molecular, cellular, synaptic and network pathologies that underlie epilepsy. Steve’s work pioneered the world’s first genetic test in epilepsy, identified dysfunctional axon segment as a determinant of seizure susceptibility, and discovered novel excitability-inducing changes in neuronal morphology. He received his BSc with Honors and Ph.D. degrees from the University of Melbourne and has authored dozens of peer-reviewed publications on the cellular and molecular biology of neurological disorders.

STUART CHAFFEE Chief Business Officer
Stuart Chaffee

Chief Business Officer

STUART CHAFFEE

Chief Business Officer

Stuart joined Praxis from Atlas Venture, where he was an Entrepreneur-In-Residence and Co-Founder of Kymera Therapeutics, a targeted protein degradation company. Prior to Atlas, Stuart spent five years at Biogen where he held roles of increasing responsibility across Finance, Business Development, Program Leadership, and Corporate Strategy. Stuart advised biopharma clients on numerous engagements while at Leerink Partners, a healthcare-focused investment bank, and was one of the founding employees at Zafgen, a biotech company advancing several programs in obesity and metabolic disease. Stuart started his career as a medicinal chemist at Amgen where he led numerous programs in oncology and neurodegeneration. He holds a BS with highest honors from the College of William and Mary, a PhD in synthetic organic chemistry from Yale University, and an MBA in finance from The Wharton School at the University of Pennsylvania.

MARION WITTMANN Head of Biology
Marion Wittmann

Head of Biology

MARION WITTMANN

Head of Biology

Marion leads the company’s efforts around the biology of neurological and psychiatric disorders. She joined Praxis from Biogen where she spent five years leading the company’s electrophysiology group, and most recently as Director of the company’s flagship Alzheimer’s research efforts where she transitioned multiple programs into clinical development. Prior to Biogen, Marion spent nine years at Merck where she led cross-functional efforts across the company’s small molecule neurology portfolio. Marion received her undergraduate and doctoral degrees with highest honors in Neuroscience from the University of Tubingen.

Gabriel Martinez

Head of Chemistry

GABRIEL MARTINEZ

Head of Chemistry

Gabriel leads the company’s chemistry efforts, bringing deep expertise across multiple therapeutic areas and adjacent functionalities. Prior to joining Praxis, Gabriel spent several years at Sage Therapeutics where he was responsible for managing all of the company’s medicinal chemistry activities that successfully brought forward five development candidates. He previously led small-molecule anti-infective efforts at Astra Zeneca and started his career with six years at Vertex where he spearheaded a number of kinase programs in oncology and immunology. Gabriel received his BSc and MS degrees from Universitat de Barcelona in Spain and his PhD from Queen Mary, University of London.

Board of Directors

Ari Brettman, M.D.

Principal, Clarus Funds

Thomas Dyrberg, M.D.

Managing Partner, Novo Ventures

Nick Galakatos, Ph.D.

Chairman of the Board, Co-Founder and Managing Director, Clarus Funds

Kiran Reddy, M.D., MBA

President and CEO

Al Sandrock, M.D., Ph.D.

CMO, EVP, Neurology Discovery, Biogen

Stefan Vitorovic, M.S., MBA

Co-Founder, Managing Director, Vida Ventures

Bill Young, MBA

Former CEO, Monogram Biosciences

Scientific Founders

David Goldstein, Ph.D.

Director of the Institute for Genomic Medicine, Professor of Genetics and Development, Columbia University

Steven Petrou, Ph.D.

Director of the Florey Institute of Neuroscience and Mental Health

Ed Scolnick, M.D.

Former Director of the Stanley Center at MIT and former President of Merck Research Labs